J Cancer 2018; 9(1):81-91. doi:10.7150/jca.21989

Research Paper

Adjuvant Chemotherapy Improves Survival in Stage III Gastric Cancer after D2 Surgery

Shin-Chun Chang1, Keng-Hao Liu1, Chia-Yen Hung2,3, Chun-Yi Tsai1, Jun-Te Hsu1, Ta-Sen Yeh1, Jen-Shi Chen2, Yung-Chia Kuo2, Yu-Shin Hung2, Wen-Chi Chou2,4✉

1. Department of Surgery, Chang Gung Memorial Hospital at Linkou, 5 Fu-Hsing Street, Kwei-Shan Shiang, Taoyuan, Taiwan;
2. Department of Hematology and Oncology, Chang Gung Memorial Hospital at Linkou, 5 Fu-Hsing Street, Kwei-Shan Shiang, Taoyuan, Taiwan;
3. Department of Hema-Oncology, Division of Internal Medicine, Mackay Memorial Hospital, Taipei, Taiwan;
4. Graduate Institute of Clinical Medical Sciences, College of Medicine, Chang Gung University, Taoyuan, Taiwan.

Abstract

Background: Stage III gastric cancer is characterized by locally advanced disease with varying anatomic extent as measured by the 7th edition of the American Joint Committee on Cancer (AJCC) staging system. There are no prognostic factors specifically identified in patients with stage III gastric cancer following extended lymph node dissection (D2) surgery.

Materials and Methods: From 2007 to 2014, 534 patients with stage III gastric cancer underwent radical gastrectomy and D2 dissection at the Chang Gung Memorial Hospital. Patients' characteristics and the impact of adjuvant chemotherapy were analyzed using univariate and multivariate analyses to identify variables associated with overall survival (OS) and disease-free survival (DFS).

Results: There were 320 deaths (60.0%) and 284 recurrences (53.2%) by the end of the study. The median OS and DFS were 30.7 months (95% confidence interval [CI]: 27.5-33.9) and 26.4 months (95% CI: 21.2-31.6), respectively. The multivariate analysis identified 7 variables that were independent prognostic factors both for OS and DFS including ratio of metastatic lymph nodes to total resection lymph nodes, carcinoembryonic antigen level, Eastern Cooperative Oncology Group performance status, gastrectomy method, vascular invasion, surgical margin, and adjuvant chemotherapy. Patients with stage IIIA-IIIC disease who received adjuvant chemotherapy had better OS and DFS outcomes than those who did not.

Conclusions: Our study identified several independent prognostic factors that might help determine the appropriate counseling patients following surgical treatment. D2 surgery alone was inadequate to achieve long-term survival. As the only correctable independent prognostic factor, postoperative adjuvant chemotherapy should be recommended for eligible patients with stage III gastric cancer.

Keywords: stage III gastric cancer, survival outcome, prognostic factor, adjuvant chemotherapy.

This is an open access article distributed under the terms of the Creative Commons Attribution (CC BY-NC) license (https://creativecommons.org/licenses/by-nc/4.0/). See http://ivyspring.com/terms for full terms and conditions.
How to cite this article:
Chang SC, Liu KH, Hung CY, Tsai CY, Hsu JT, Yeh TS, Chen JS, Kuo YC, Hung YS, Chou WC. Adjuvant Chemotherapy Improves Survival in Stage III Gastric Cancer after D2 Surgery. J Cancer 2018; 9(1):81-91. doi:10.7150/jca.21989. Available from http://www.jcancer.org/v09p0081.htm